The financing will support the commercialisation efforts of Okami’s catheter-based technologies for peripheral vascular occlusion. Credit: Patho / Wiki Commons.

Okami Medical, the second portfolio company of medical device incubator Inceptus Medical, has raised fresh funds to support the commercialisation of catheter-based technologies for peripheral vascular occlusion.

The company raised $7.2m in a Series D financing round, which was led by US Venture Partners.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The round was also joined by the members of Okami’s board of directors and medical device industry veterans.

Okami’s LOBO Vascular Occlusion System is a single-device solution for the occlusion of a range of arterial targets, eliminating the need for multiple embolic devices.

By combining a patented design with proprietary HDBRAID technology, the system generates a highly occlusive pore structure that substantially reduces blood flow and accelerates vessel closure.

The technology platform enables the successful treatment of a diverse set of conditions by providing fast and efficient closure of blood vessels throughout the body.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The LOBO system was granted 510(k) clearance by the US Food and Drug Administration (FDA) for the occlusion of peripheral arteries.

Okami president and CEO Bob Rosenbluth said: “We are pleased to continue to work with investors who have supported us in our mission to create and foster innovative concepts into successful companies, including Inari Medical, Sequent Medical and MicroVention.

“We will use these funds to support and accelerate Okami’s commercial and technology development programs.”

Founded in 2017, Okami Medical focuses on the development of intuitive devices for the occlusion of peripheral vessels.

Peripheral vascular occlusion is a circulatory condition caused by reduced blood flow to the limbs due to narrowed blood vessels.